

An Overview of Radiation Countermeasure Development in Radiation Research from 1954 to 2024

Authors: Kiang, Juliann G., Cannon, Georgetta, and Singh, Vijay K.

Source: Radiation Research, 202(2) : 420-431

Published By: Radiation Research Society

URL: <https://doi.org/10.1667/RADE-24-00036.1>

The BioOne Digital Library (<https://bioone.org/>) provides worldwide distribution for more than 580 journals and eBooks from BioOne's community of over 150 nonprofit societies, research institutions, and university presses in the biological, ecological, and environmental sciences. The BioOne Digital Library encompasses the flagship aggregation BioOne Complete (<https://bioone.org/subscribe>), the BioOne Complete Archive (<https://bioone.org/archive>), and the BioOne eBooks program offerings ESA eBook Collection (<https://bioone.org/esa-ebooks>) and CSIRO Publishing BioSelect Collection (<https://bioone.org/csiro-ebooks>).

Your use of this PDF, the BioOne Digital Library, and all posted and associated content indicates your acceptance of BioOne's Terms of Use, available at www.bioone.org/terms-of-use.

Usage of BioOne Digital Library content is strictly limited to personal, educational, and non-commercial use. Commercial inquiries or rights and permissions requests should be directed to the individual publisher as copyright holder.

BioOne is an innovative nonprofit that sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research libraries, and research funders in the common goal of maximizing access to critical research.

An Overview of Radiation Countermeasure Development in *Radiation Research* from 1954 to 2024

Juliann G. Kiang,^{a,b,c,1} Georgetta Cannon,^a Vijay K. Singh^{a,b}

^a Scientific Research Department, Armed Forces Radiobiology Research Institute; ^b Department of Pharmacology and Molecular Therapeutics, School of Medicine; ^c Department of Medicine, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland

Kiang JG, Cannon G, Singh VK. An Overview of Radiation Countermeasure Development in *Radiation Research* from 1954 to 2024. *Radiat Res.* 202, 420–431 (2024).

Preparation for medical responses to major radiation accidents, further driven by increases in the threat of nuclear warfare, has led to a pressing need to understand the underlying mechanisms of radiation injury (RI) alone or in combination with other trauma (combined injury, CI). The identification of these mechanisms suggests molecules and signaling pathways that can be targeted to develop radiation medical countermeasures. Thus far, the United States Food and Drug Administration (U.S. FDA) has approved seven countermeasures to mitigate hematopoietic acute radiation syndrome (H-ARS), but no drugs are available for prophylaxis and no agents have been approved to combat the other sub-syndromes of ARS, let alone delayed effects of acute radiation exposure or the effects of combined injury. From its inception, *Radiation Research* has significantly contributed to the understanding of the underlying mechanisms of radiation injury and combined injury, and to the development of radiation medical countermeasures for these indications through the publication of peer-reviewed research and review articles. © 2024 by Radiation Research Society

INTRODUCTION

Radiation exposure has been known to be a double-edged sword since the discovery of radioactivity. The usefulness of diagnostic and therapeutic radiation had to be balanced against increased cancers among nuclear medicine and radiologic technicians. Deadly radiation exposures during warfare eventually translated to the development of life-saving treatments when the exposure could be limited to otherwise deadly cancerous tissues. Right alongside the drive to develop more powerful bombs was the drive to discover ways of limiting radiation-induced damage to biological systems.

¹ Correspondence: Juliann G. Kiang, Ph.D., Armed Forces Radiobiology Research Institute, 4555 South Palmer Road, Building 42, Bethesda, Maryland, 20889-5648; email: juliann.kiang@usuhs.edu; 301-295-1076 (Office).

Initially the development of countermeasures was based on radiation physics. Shielding and distance were used to protect X-ray equipment operators. Some of the earliest countermeasures approved by the United States Food and Drug Administration (U.S. FDA) basically limited the time of the exposure by preventing retention of radioactive isotopes [e.g., potassium iodide, KI for ¹³¹I exposure (1–3), Zn- and CA-DTPA (diethylenetriamine pentaacetate) for exposure to transuranic or rare earth radionuclides (4–6), and Prussian Blue for ¹³⁷Cs and ²⁰¹thallium exposure (7, 8)]. These are useful but limited both in efficacy and in range of application.

The development of better countermeasures required extensive research into the complex and interactive mechanisms in play during radiation-induced damage. After more than 60 years of such research, more generalized countermeasures began to gain regulatory approval for treatment of the hematological disorder attributed to radiation, and gradually countermeasures for external radiation exposure injuries are being discovered and developed. Since its inception in 1954, *Radiation Research* has furthered this research mission.

This article focuses on work documenting the development of radiation injury (RI) and combined injury (CI) countermeasures published in *Radiation Research* with minimal citation of articles published in other journals (mostly for background material, U.S. FDA approvals and a few additional reviews). We have further limited our write-up to the more successful and widely tested countermeasures using animal models since it is impossible to cover all agents tested in all possible models. Searches were performed in PubMed and Google Scholar, using general radiation countermeasure terms and specific countermeasure names (in all fields for PubMed) with and without the additional qualification of *Radiation Research* as the journal of publication.

The authors recently performed a comprehensive literature search to systematically catalog the radiation-induced alterations of multi-omics profiles and biomarkers, and associated radiation countermeasures (9). Also, since 2005, the Radiation and Nuclear Countermeasures Program of the National Institute of Allergy and Infectious Diseases has funded countermeasures research and published many reviews, workshop proceedings, and details of regulatory approval for countermeasures in *Radiation Research* (10–24).

Radiation countermeasures currently fall into three categories as shown in Tables 1–3: Protective, mitigative and therapeutic (25, 26). Currently approved radioprotectors (administered before exposure) are for very limited types of exposure or conditions. All currently approved mitigative agents (used shortly after exposure) are limited to decorporation of specific agents or address the hematopoietic acute radiation syndrome (H-ARS). More recently, therapeutic agents generally administered after radiation exposure, sometimes for an extended period and intended to address long-term effects, are being developed (Table 3). Countermeasures that have shown efficacy as mitigators may also have protective effects and vice versa, and many of the investigational drugs are being tested in all three capacities. *Radiation Research* has helped advance the development of most of these medical countermeasures, either through publication of the data that elucidated the mechanisms they target, or by publication of the data demonstrating their efficacy and safety.

MEDICAL COUNTERMEASURES FOR RADIATION INJURY PUBLISHED IN *RADIATION RESEARCH*

The detrimental effects of radiation are known to be dependent on the dose, dose rate, quality, shielding, and the distance from the radiation source. Different syndromes, including acute, delayed, late, and chronic

syndromes, are manifested depending on radiation exposure time, duration, and radiation quality. ARS was further classified by organs involved which were sensitive to radiation, namely H-ARS, gastrointestinal (GI-ARS), and neurovascular (NV-ARS) sub-syndromes. In some tissues such as lung, kidney, and skin, acute exposure results in delayed effects (delayed effects of acute radiation exposure, DEARE).

1954–1980

The first publication on cysteine as a radioprotector was published in 1949 in *Science* (27). From its outset in the mid-50s, *Radiation Research* published many articles on the molecular effects of ionizing radiation and on *in vivo* effects (28, 29), studies which were necessary for the rational design of radiation medical countermeasures. The idea of reducing radiation damage by preventing the internal deposition of plutonium was published in 1955 (30) and the use of DTPA as a radiation countermeasure for retained monomeric plutonium was published in *Radiation Research* 12 years later (5). In 1961, the idea of dietary supplementation as a radiation countermeasure was proposed (31), and beginning in 1975, amifostine (originally designated WR-2721) was also advanced as a radiation countermeasure against H-ARS (32).

TABLE 1
Countermeasures: Protection

| Agent | Activity/limitations | Refs. |
|---|---|-----------------------|
| U.S. FDA approved: limited use radioprotectors | | |
| Potassium iodine | For ¹³¹ I exposure, blocks uptake, narrow window | (2) |
| Amifostine (thiol scavenger) Ethyol®, WR-2721, WR-1065 | Used to prevent xerostomia when salivary glands are irradiated, high tox., narrow delivery window, IV | (45, 48, 117) |
| Palifermin (n-truncated KGF, KGF is part of the FGF family), Kevivance™ | Used to prevent oral mucositis in patients receiving stem cell ablation/transplantation, epithelial repair/protection | (36) |
| Experimental drugs - protection | | |
| BIO 300 (genistein) IND FT | Polyphenolic estrogen receptor β agonist | (56, 83, 118) |
| Gamma-tocotrienol IND | Vitamin E, antioxidant | (41, 42, 60, 61, 119) |
| EX-RAD IND | Small molecule kinase inhibitor, chlorobenzylfulfone derivative | (40) |
| 5-androstenediol (steroid) IND | Development discontinued then initiated again. | (37) |
| CBLB502 (truncated flagelin) NDA entolimod, KMRC011, GP532 IND | TLR5 binder, induces G-CSF, hold 2019 (immunogenicity), now lifted, reengineered GP532, lacks immunogenicity | (75) |
| HOPO ligands IND hydroxypyridinonate ligand | Decorporation of actinides | (4, 77) |
| CBLB613 | TLR 2/6 agonist | (120) |
| N-acetylcysteine | Free radical scavenger | (44) |
| Alpha-tocopherol succinate | Vitamin E, antioxidant | (52) |
| Nutraceuticals | Increases in antioxidants | (31, 43, 59) |
| Probiotics | Regrow and promote good microbiota | (82) |
| Statins | Lower LDL cholesterol in blood | (46, 47, 67) |
| Metformin, biguanides | Diabetes control | (70, 74) |

TABLE 2
Countermeasures: Mitigation

| Agent | Activity/limitations | Ref.(s) |
|---|--|--------------------------|
| U.S. FDA Approved Radiation Mitigation: Limited Use | | |
| Prussian Blue Radiogardase® | For ¹³⁷ Cs and ²⁰¹ thallium exposure | (121) |
| Potassium iodine | For ¹³¹ I exposure, blocks uptake, narrow window | (2) |
| Zn-DTPA; CA-DTPA (chelators) | Transuranic or rare earth radionuclide exposure | (4, 5) |
| Silverlon | For radiation dermatitis and cutaneous radiation injury | (10) |
| U.S. FDA Approved Radiation Mitigation For H-ARS | | |
| pegylated-G-CSF (Neulasta, Udenyca, Stimufend) | Neutrophil mobilization | (53, 89) |
| G-CSF (Neupogen) | Neutrophil mobilization | (13, 16, 54, 55, 62, 78) |
| GM-CSF (Leukine) Sargramostim | Granulocyte and macrophage mobilization, | (13, 16, 78) |
| Nplate (Romiplostim) | Platelet production | (13, 16, 78, 79) |
| Experimental drugs - Mitigation | | |
| BIO 300 (genistein) IND FT | Polyphenolic estrogen receptor beta agonist | (56, 83) |
| gamma-tocotrienol IND | Vitamin E, antioxidant? | (41, 42, 60, 61, 119) |
| EX-RAD IND | Small molecule kinase inhibitor, chlorobenzylfulfone derivative | (40) |
| 5-androstenediol (steroid) IND | Development discontinued then initiated again | (37) |
| myeloid progenitors IND | H-ARS, GI-ARS | (49, 50) |
| CBLB502 (truncated flagellin) entolimod IND | TLR5 binder, induces G-CSF, hold in 2019, now lifted, reengineered GP532, lacks immunogenicity | (75) |
| IL12, HemaMax, IK14800, Agrez IND | Induces IL12, IL2, IFN γ) ARS–24 h post; also, CI (burn), skin | (73, 122) |
| HOPO ligands IND hydroxypyridinonate ligand | Decorporation of actinides | (4, 77) |
| CBLB613 | TLR 2/6 agonist | (120) |
| PEG-IL-11, Neumega® (BBT-059) | Platelet production, deemed too toxic post RAD, BBT-059 is a less toxic version | (38, 39) |
| Thrombopoietin receptor agonists | Platelet production | (88) |
| ACE inhibitors | DEARE, off label, no clear approval process, lung, kidney | (33, 66) |
| NLRP3 inhibitors/Nrf2 activators | GI-ARS, dermatitis Quercetin, Esomeprazole, triterpenoid RTA 408 | (63, 72, 76, 123, 124) |

1981–2000

Angiotensin converting enzyme (ACE) inhibitor CL242817 was reported in 1989 (33) to modify radiation-induced endothelium and lung fibrosis after a single dose of up to 30 Gy of gamma radiation to the hemithorax. Over the years, many more ACE inhibitors would be explored as mitigators of DEARE. Misoprostol, a prostaglandin E1 (PGE1) analog was explored as a radioprotector against fission spectrum neutron irradiation alone or in combination with amifostine in 1991 (34). Survival was improved in both mice and intestinal clonogenic cells, supporting the notion that misoprostol could be a potential treatment for GI-ARS. Later, misoprostol would be shown to reduce multiple organ DEARE in mice (35). In 1998, Savla and Waters found that keratinocyte growth factor protected the barrier function of epithelial cells in the irradiated animal airways, potentially reducing lung DEARE (36). Decorporation options were also expanded. Noteboom et al. published on the use of stable KI to protect against ¹³¹I exposure (2, 3).

2001–2010

As understanding grew about the effects of radiation on living systems, countermeasure research expanded. Steroids, cytokines and growth factors, antioxidants and statins were all explored as possible treatments. Whitnall and colleagues (2001) reported that a single subcutaneous (*sc*) dose of 5-androstenediol offered protection against H-ARS by stimulating myelopoiesis, increasing the numbers of circulating monocytes, neutrophils, natural killer (NK) cells and platelets for several weeks in CD2F1 male mice exposed to various doses of gamma radiation (37). In 2002, Van der Meeren et al. published data indicating that treatment with recombinant human interleukin-11 (IL-11) in combination with thrombopoietin (TPO) improved survival of C57BL/6J mice exposed to gamma radiation (10 or 15 Gy) compared to mice that received TPO alone due to the reduction of H-ARS effects (38). Hao et al. in 2004 demonstrated accelerated recovery of platelets, leukocytes and colony-forming bone marrow cells in non-human primates (NHP) exposed to 3 Gy of gamma radiation that were immediately treated

TABLE 3
Countermeasures: Therapeutic

| Agent | Activity/limitations | Ref.(s) |
|--|--|------------------------|
| Experimental drugs | Therapeutic | |
| BIO 300 (genistein) IND FT | Protection from DEARE-lung | (83, 118) |
| AEOL 10150 (antioxidant) IND, FT | Protection from DEARE-lung | (68, 71, 125) |
| TGF-beta Receptor 1 inhibitor SKI2162, LY2109761, IPW-5371 | Mitigate pulmonary and cardiac injury by increasing TGF- β signaling | (69) |
| ACE inhibitors | Protection from DEARE-lung, renal, optic | (33, 65, 66, 126, 127) |
| 16,16 Dimethyl Prostaglandin E2 (PGE2) | Protection from DEARE lung, heart, optic | (35, 128) |
| Statins | Protection from DEARE-heart | (46, 67) |

with IL-11 (39). This work would later progress using the pegylated version of IL-11, BBT-059. In 2009, Ghosh and colleagues demonstrated that Ex-Rad as a radioprotector increased survival in C3H/HeN mice after gamma irradiation (7.5 or 8 Gy) (40) and Berbee and colleagues reported that gamma-tocotrienol mitigated intestinal radiation injury and vascular oxidative stress in CD2F1 mice exposed to 8.5 Gy of gamma radiation (41). In 2010, Kulkarni et al. reported that pre-treatment with gamma-tocotrienol protected hematopoietic stem and progenitor cells in CD2F1 mice after 7 or 8 Gy of gamma irradiation (42). Both Ex-Rad[®] and gamma-tocotrienol appeared to have efficacy against both H-ARS and GI-ARS. 5-androstenediol, gamma tocopherol and Ex-Rad would all go on to receive U.S. FDA investigational new drug (IND) status.

Brown et al. found that an antioxidant supplementation diet containing L-selenomethionine, sodium ascorbate, N-acetyl cysteine, alpha-lipoic acid, alpha-tocopherol succinate and co-enzyme Q10, started 24 h after irradiation reduced mortality in C57BL/6 mice after 8 Gy total-body gamma irradiation, reducing both H-ARS and GI-ARS (43). Jia et al. found that the antioxidant N-acetyl-cysteine administered either before or immediately after irradiation improved the survival of C57BL/6 mice that received a 20 Gy abdominal X-ray exposure (44).

Research also continued into DEARE countermeasures. In 2002, Vujaskovic et al. reported that amifostine reduced both the accumulation of macrophages and the expression/activation of lung tissue growth factor beta 1 in Fisher 344 rats exposed to a single partial-body (right hemithorax) X-ray exposure of 28 Gy (45) demonstrating amifostine's role in reducing lung DEARE. Williams et al. published that lovastatin increased survival in C57BL/6 mice exposed to 15 Gy whole-lung gamma irradiation in 2004 (46). In 2005, pravastatin was shown to reduce radiation-induced (5 or 10 Gy of gamma radiation) microvascular activation in cultured human lung endothelial cells resulting in the reduction of inflammatory and thrombotic responses (47).

In other studies, Guo and colleagues used athymic nude mice irradiated with 30 Gy X rays to the head as a model for oral cavity mucositis and reported that pre-transfection of the superoxide dismutase 2 gene reduced radiation-

induced epidermal thinning and ulceration in 2003 (48). In 2008, Otsuka et al. primed C57BL/6 mice with low-dose acute X rays (0.5 Gy) 2 weeks prior to a high-dose (6–8 Gy) challenge exposure and demonstrated that rapid myeloid recovery was a possible mechanism of the whole-body radio-adaptive response (49).

2011–2020

In this decade, the first growth factors were approved by the U.S. FDA for mitigation of H-ARS, and antioxidant research progressed. New treatment options such as ACE inhibitors, toll-like receptor (TLR) ligands, and myeloid progenitor cells were considered.

In 2012, myeloid progenitors were reported to improve survival in mice when administered several days after lethal doses of gamma rays or X rays (50). Administration of these cells mitigated death from H- and GI-ARS at radiation doses up to 15 Gy (gamma radiation, CD2F1 mice), which are doses that cause mice to succumb to multi-organ failure; the dose reduction factor of 5 million mouse myeloid progenitor cells (mMPC) administered 24 h postirradiation to CD2F1 mice was 1.73. Separately, using CD2F1 mice, CBLB613 (a naturally occurring mycoplasma-derived lipopeptide ligand for TLR 2/6) was assessed for toxicity, immunogenicity, radioprotection, radiomitigation, and pharmacokinetics (51). CBLB613 significantly protected mice against H-ARS after a lethal dose of gamma rays. Alpha-tocopherol succinate was also shown to protect mice against radiation-induced GI injury (total-body doses from 9.5 to 12 Gy) (52).

Also in 2012, Farese et al. indicated that Neupogen[®] improved neutrophil recovery (53) and survival (54) in a NHP model after 6 and 7.5 Gy of X-ray radiation (respectively). These studies were pivotal in the U.S. FDA approval of Neupogen[®] and Neulasta[®] for H-ARS treatment under the animal rule in 2015. The kinetics of neutrophil recovery in mice after irradiation with gamma rays or protons (0.5, 1 or 2 Gy) and treatment with vehicle or Neupogen[®] were reported (55).

In 2013, Ha et al. reported that genistein protected the mouse hematopoietic system and prevented proinflammatory factor induction after 9.25 Gy gamma irradiation (56).

Li et al. found delta-tocotrienol protected mice from 11 Gy gamma-radiation-induced GI injury (57). In 2014, captopril, an ACE inhibitor, combined with gentamicin and levofloxacin exhibited its ability to increase survival in mice after 9.5 Gy gamma irradiation (58) and Roche and colleagues suggested that high levels of a dietary supplement with Vitamins A, C, and E protected GI transport against chronic low dose gamma radiation in mice (59).

In 2016, gamma tocotrienol was demonstrated to protect NHPs and improve complete blood count (CBC) when the animals were exposed to three different doses of total-body gamma irradiation (60). Using this agent in a murine model, proteomic changes in the spleen of animals exposed to 7 Gy of gamma radiation were examined to elucidate possible mechanisms of action of this promising prophylactic countermeasure (61). In 2017, Satyamitra et al. found that Neupogen[®] increased survival and hematopoietic recovery in 4 strains of irradiated mice with different radiosensitivities (using ⁶⁰Co gamma radiation at the LD_{70/30} for each strain) and that a more limited dosing schedule was more effective across various strains (62).

Horton et al., studying DEARE in skin, indicated that adding quercetin, an antioxidant, to chow inhibited skin fibrosis in mice that received 35 Gy of X rays to the hind leg (63). Silverlon burn contact dressing was approved by the U.S. FDA for a limited range of cutaneous radiation injury and radiation dermatitis (10, 64). Gao et al. published that enalapril (an ACE inhibitor) started 35 days after irradiation of the whole thorax with 13 Gy mitigated radiation-induced pneumonitis and pulmonary fibrosis (65). ACE inhibitors combined with a syngeneic bone marrow transplant were found to mitigate radiation-induced multiple organ injury in rats (11 to 11.5 Gy X irradiation) (66). Zhang et al found that atorvastatin mitigated cardiac fibrosis in rats after local heart irradiation given in 7 daily fractions of 3 Gy for a total of 21 Gy (X irradiation) (67). Murigi et al. reported that AEOL 10150 (a superoxide dismutase mimic) was a mitigator of radiation-induced lung injury in mice after whole-thorax lung irradiation (WTLI) (14.6 Gy of X rays) (68). Furthermore IPW-5371, a transforming growth factor (TGF)-beta receptor inhibitor, proved to mitigate radiation-induced late effects in mice that received a 5 Gy dose of total-body X irradiation immediately followed by a 6.5 Gy irradiation to the thorax (69). In 2017, Wang et al. reported that treatment with metformin attenuated radiation-induced pulmonary fibrosis in rats (20 Gy of X rays to the right thorax) (70) and AEOL 10150, an antioxidant, was found to mitigate radiation-induced lung injury in NHPs with 10.74 Gy (X irradiation) when the drug was administered for an extended period of time (71). AEOL 10150 would also go on to receive U.S. FDA IND status for lung DEARE.

In 2014, topical application of the synthetic triterpenoid RTA408, which activates the antioxidative transcription factor Nrf2 and inhibits nuclear factor kappa B (NF-kappa B)

was shown to protect mice from radiation-induced dermatitis after repeated 10 Gy irradiations (X rays) limited to an area of skin on the back (72). Gerber et al. found IL-12 preserved the cutaneous physical and immunological barrier function after irradiation (a combination of 6 Gy total-body gamma irradiation and 40 Gy beta irradiation from a strontium-90 applicator to the skin) of C57BL/6 hairless mice (73). Pre-treatment or post-treatment with metformin alone or in combination with several other drugs exhibited a significant improvement after irradiation (7 Gy X irradiation) as measured by spleen nodule formation 13 days postirradiation (74). TLR5 agonist entolimod mitigated radiation-induced epithelial damage in mice during fractionated head and neck irradiation (5 fractions of 5, 6 or 7 Gy of X radiation) when used immediately before or after irradiation (75). In 2019, topical esomeprazole (a proton pump inhibitor) mitigated radiation-induced dermal inflammation and fibrosis in mice that received 2 × 15 Gy X irradiation to the left flank (76).

A safety and efficacy study for two new decorporation agents, 3,4,3-LI(1,2-hydroxypyridinone (HOPO) and 5-LIO-(Me-3,2-HOPO), was published in 2013 (77). These agents would also receive U.S. FDA IND status.

2021–2024

Granulocyte-macrophage colony-stimulating factor (GM-CSF), used alone, was found to be effective in mitigating H-ARS in NHP exposed to 6.55 or 7.13 Gy of gamma radiation (78), or in combination with multi-cytokine therapy in humans who received accidental heterogeneous doses of ⁶⁰Co or ¹⁹²Ir gamma rays (79). A pediatric model for H-ARS was established in mice and used to demonstrate that Neulasta[®] (pegylated G-CSF) was an effective countermeasure for H-ARS but not for DEARE after irradiation with 550 to 875 cGy of gamma radiation (80, 81). Oral administration of the probiotic *Lactobacillus reuteri* expressing IL-22 was shown to facilitate intestinal radio-protection after a single fraction of 9.25 Gy total-body irradiation (TBI), 15 Gy partial-body irradiation with one hind limb shielded (5% of bone marrow), or 19.75 Gy whole-abdominal irradiation (X rays) (82). Using a murine model and total-body gamma radiation (7.75 Gy of ⁶⁰Co gamma radiation), BIO 300, a nanosuspension of genistein, in combination with Neulasta[®], was found to protect against DEARE lung damage in mice, reducing both inflammation and fibrosis, neither of which was significantly affected by Neulasta[®] alone (83). BIO 300 has received U.S. FDA IND status.

Countermeasures on the Horizon

As stated above, the U.S. FDA has approved a limited number of radiation countermeasures for very specific exposures/circumstances (see Tables 1 and 2). For ARS, however, only H-ARS has limited radiation mitigation options. The options include Leukine[®], Neupogen[®], and

Neulasta® [and the Neulasta® biosimilars Stimufend® (peg-fpgk), and Udenyca® (peg-cbqv)], all of which stimulate recovery of neutrophils, and Nplate® which improves platelet recovery. These H-ARS radiomitigators are recombinant growth factors or growth factor receptor agonists that were developed for other indications, and recently repurposed to treat H-ARS (84). No radioprotector for H-ARS or mitigator for GI-ARS or for DEARE has yet been approved by regulatory agencies for human use (85, 86). Several radiation countermeasures developed for external exposure, such as entolimod/CBLB502, Ex-Rad/Recilisib, BIO 300 (genistein), myeloid progenitors/CLT-008, 5-androsteinediol, and PLX-R18 (placental-derived cellular therapy) have received U.S. FDA IND status and as shown above, *Radiation Research* publications have disseminated critical information regarding the development of most of them (85). Some of these agents have shown promise as protectors, mitigators and/or therapeutic countermeasures, with effects on multiple tissues. Several additional agents have shown great promise as countermeasures and are currently being tested in pre-clinical animal studies (87).

The majority of the countermeasures investigated have been studied as single therapies. As more countermeasures with different mechanisms of action have become available, the use of multiple drugs either simultaneously or in sequence has also become an attractive treatment option, known as the polypharmacy approach. Examples of a few combination therapies that have been tested so far include Neulasta® (or a biosimilar) combined with: ALXN4100TPO (TPO receptor agonist) (88), L-citrulline (89), ghrelin (90), ciprofloxacin (91) or BIO 300 (83). Other combinations include IL-11 plus StemTPO plus enrofloxacin (38), captopril (ACE inhibitor) plus gentamicin plus levofloxacin (58), metformin in combination with sulfhydryl-containing drugs (74), GM-CSF plus cytokines (79), pegylated G-CSF plus stem cell factor plus romiplostim (79), 16, 16-dimethyl prostaglandin E2 plus lisinopril (ACE inhibitor) (92) or plus amifostine (93), amifostine plus glucan (94), a multiple antioxidant dietary supplement containing L-selenomethionine, sodium ascorbate, N-acetyl cysteine, alpha-lipoic acid, alpha-tocopherol succinate and co-enzyme Q10 (43), and gamma tocotrienol plus pentoxifylline (41). A recent meeting discussed new developments in polypharmacy for radiation injury (95, 96).

COMBINED RADIATION INJURY (CI): RADIATION INJURY (RI) WITH ANOTHER TRAUMA

Often, victims exposed to radiation also present after blast with additional traumas such as hemorrhage, blast burns, wounds or infections. Combined radiation injuries (CI) were documented at Hiroshima and Nagasaki, Japan, where 60–70% of radiation victims simultaneously received thermal burns and ten percent of the 237 victims at the Chernobyl reactor meltdown received radiation exposure and thermal burns. Either radiation injury or combined injury

induce body weight loss and mortality in a radiation dose-dependent manner. However, in mouse models, combined injury exhibits an earlier onset of body weight loss, earlier mortality and delayed wound healing if wound trauma occurred (12, 97).

In the 1970s, the Armed Forces Radiobiology Research Institute (AFRRI) began combined injury investigations. In a murine model, radiation exposure followed by burns or wounds further reduced survival compared to burns alone, wounds alone or radiation exposure alone, and radiation exposure delayed wound healing time. In addition to penetrating skin wounds (98) and burn, animal models for combined injury with hemorrhage and infection were established at AFRRI. Besides worsened survival, body weight loss and delayed wound healing, combined injury with radiation plus wound or plus hemorrhage appeared to amplify and prolong skeletal tissue loss. Survivability following combined injury with radiation and wounding is related to the size of the wound (99), although some reports indicated that subcutaneous wounding after irradiation increased survival of irradiated mice (100, 101). Injuries before or at the time of irradiation tend to decrease survivability (97).

As shown in Table 2, the U.S. FDA has approved a few treatments as mitigators of H-ARS (84, 102). Some of these drugs are less useful for treating combined injury (103). The criteria for determining whether a drug/agent is considered as a combined injury medical countermeasure must include improved 30-day survival, reduced body weight loss, and improved wound healing time (for radiation and wound combinations), when the animal is exposed to radiation at LD_{50/30}. Several drugs/agents have been tested, but many of them failed to improve survival, mitigate body weight loss or reduce the delay in wound healing time. Table 4 lists mitigators that have shown efficacy toward CI.

MEDICAL COUNTERMEASURES FOR COMBINED RADIATION INJURY (CI)

In the case of radiation combined with wounds, natural choices for treatments included anti-inflammatory agents, antibiotics and agents that encouraged natural wound healing processes that were disrupted by radiation such as laminin deposition. In 2009, we reported that COX-2 inhibitors, celecoxib, and meloxicam, did not improve 30-day survival in B6D2F1 female mice that were exposed to 9.75 Gy of gamma radiation followed by wound trauma (104). In 2011, matrix metalloproteinase 2 (MMP2) inhibitor 1,10-phenanthronine, was found to inhibit MMP2 expression and then increase laminin 332 deposition in the skin in rats that were exposure to X rays (10–40 Gy) followed by wounding (105). In 2014, Zawaski et al. (99) found that Betadine or triple antibiotic ointment increased wound healing in rats exposed to 6 or 7.5 Gy and subjected to a skin wound, but did not improve 30-day survival after CI. Interestingly, Alpha-difluoromethylornithine prevented

TABLE 4
Countermeasure treatment for CI

| Agent | Activity/limitations | Ref.(s) |
|---|--|---------|
| Cox-2 inhibitors: Celecoxib and meloxicam | Failed to improve 30-day survival after CI | (104) |
| MMP2 inhibitor: 1,10-phenanthroline | Increased laminin 332 deposit to the skin and accelerate skin wound healing after CI | (105) |
| Betadine | Increased wound healing but did not improve 30-day survival after CI | (99) |
| Triple antibiotic ointment | Increased wound healing but did not improve 30-day survival after CI | (99) |
| Timolol beta-adrenergic receptor antagonist | Increased wound healing after CI | (109) |
| Alpha-difluoromethylornithine | Prevented hippocampus-dependent cognitive impairment after CI | (106) |
| Ciprofloxacin | Increased IL-3 in blood, 30-day survival, and ATP production after CI | (91) |
| Captopril+ gentamicin+ Levofloxacin | Increased 30-day survival after RI but not CI | (58) |
| Neulasta + Alxn4100TPO | Increased 30-day survival after RI and CI | (88) |
| Neulasta + L-Citrulline | No significantly increased survival after CI | (89) |
| Mouse Ghrelin | Increased survival, mitigated H-ARS, GI-ARS, and brain hemorrhage after CI | (107) |

hippocampus-dependent cognitive impairment in male C57BL/6 mice exposed to 4 Gy of gamma radiation after combined injury (106).

Ciprofloxacin is a U.S. FDA-approved fluoroquinolone antibiotic that has been included in the Strategic National Stockpile for dispensing during a national emergency to control bacterial infection. Besides the antimicrobial activity, several groups reported immunomodulatory effects of ciprofloxacin in rodent models and human clinical trials improving a wide spectrum of conditions. In 2015, the authors found that oral administration of ciprofloxacin improved 30-day survival, mitigated body weight loss, accelerated skin-wound healing, upregulated IL-3, and preserved ATP production in B6D2F1 female mice exposed to 9.5 Gy ⁶⁰Co gamma rays followed by wound trauma (91).

We also investigated combined treatments (aka poly-pharmacy) to maximize countermeasure development to concurrently treat both radiation injury and CI. When B6D2F1 female mice were exposed to 9.5 Gy of ⁶⁰Co gamma radiation alone or followed by wound trauma, captopril in drinking water in combination with topical gentamicin and oral levofloxacin failed to improve 30-day survival after CI, but was effective at increasing survival after radiation injury (58). In 2017, we reported that combined treatment with Neulasta[®] and Alxn4100TPO increased 30-day survival of B6D2F1 female mice exposed to 9.5 Gy of ⁶⁰Co gamma rays alone (RI) or followed by wound trauma (CI). Alxn4100TPO is a TPO receptor agonist that significantly increased megakaryocytes in bone marrow and platelets in circulation (88). In 2021, using the same animal model, the authors reported that treatment with Neulasta[®] and L-Citrulline administered 24 h after combined injury improved survival, although this did not reach statistical significance (89). The authors also studied mouse ghrelin administered to mice after radiation injury or CI. Mouse ghrelin significantly increased 30-day survival, mitigated H-ARS, GI-ARS, and decreased brain hemorrhage after combined injury (107).

Agents that have been successful in alleviating combined radiation exposure with burn injury include verapamil, chitosan-wrapped human defensin 5, glucagon-like peptide 2, or cervical sympathetic ganglia block (108). The beta 2 adrenergic receptor agonist timolol improved epidermal burn wound closure after radiation exposure combined with burn injuries (109). Finally, the burn/wound contact dressing Silverlon has received U.S. FDA approval for use in treating wounds/burns and dermatitis after irradiation (10).

Additional drugs/agents/procedures efficacious at improving 30-day survival for combined injury have been published elsewhere. These include Neupogen[®], Neulasta[®], Alxn4100TPO, mouse mesenchymal stem cells (MSCs), gentamicin, Silvadene, WR-151327, amifostine, bone marrow transplantation, Neulasta[®] and ghrelin, Neulasta[®] and ciprofloxacin, S-TDCM and gentamicin (12, 18, 97).

PERSPECTIVES ON COMBINED INJURY COUNTERMEASURES

Among all U.S. FDA-approved drugs and non-U.S. FDA-approved candidates, combined therapy with MSCs and Neulasta[®] should stand a great chance to significantly increase survival after combined injury as well as radiation injury, because whole bone marrow (containing progenitor stem cells and MSCs) transplantation resulted in 100% survival after lethal CI, treatment with MSCs showed survival improvement by 30% after lethal CI, and Neulasta[®] has been demonstrated to mobilize neutrophils from bone marrow to peripheral blood. Thus, if Neulasta[®] can enhance MSC capability to save more lives after CI, then lower numbers of MSCs would be needed, which would lead to a lower chance of developing lung fibrosis later. However, the obvious drawback in using MSCs is that medical assistance from appropriately trained personnel is required, which is not feasible in a mass casualty scenario. In addition, the quality control and/or safety of MSCs are not regulated yet. On the other hand, results from the combined treatment

with a TPO mimetic and Neulasta® appeared promising to concurrently treat combined injury as well as RI.

DISCUSSION

The availability of appropriate preclinical animal models was one of the limiting factors for developing radiation medical countermeasures for radiation injury and combined injury and the identification of suitable biomarkers of radiation exposure. Now the characterization of additional animal models is well under way. For instance, radiation exposure biomarker comparisons across mice, NHPs and 2 varieties of minipigs have been performed (*110*), proteomic profiles from heart, lung, and liver samples of irradiated minipigs have been analyzed (*111*) and cutaneous models of both large swine (*112*) and minipigs are under development (*113*) to complement studies using minipigs to examine GI-ARS (*114*) and H-ARS (*115*). For investigating the radiation injury and countermeasure efficacy within large animal models however, only NHP and canine have been fully characterized. The NHP is the gold standard for drug development and U.S. FDA regulatory approval under the Animal Rule. Additional suitable large animal models for H-ARS and GI-ARS need to be developed and validated to expedite the development and regulatory approval of radiation countermeasures. Although the minipig is an intriguing model, it is in a primitive state of investigation as an ARS animal model compared to the mouse, rat, canine, and NHP. Countermeasures are typically tested in rodents using 30-day survival as the major endpoint; a 60-day survival endpoint is used in canines or NHP. These time intervals have been selected to reflect the ability of the agent to provide protection or mitigation of ARS following total- or partial-body radiation exposure. DEARE is also gaining interest in the field of radiation medical countermeasure investigation.

Only a limited number of radiation countermeasures have been fully approved by the U.S. FDA for the purpose of controlling the health hazards arising from ionizing radiation exposures. The U.S. FDA has approved ten agents that mitigate irradiation-associated injuries. Four of these agents, KI (ThyroShield), Zn-DTPA, Ca-DTPA, and Prussian Blue, are agents that bind, chelate, or block internalized radionuclides so that body-burdens of radioisotopes can be minimized. Six growth factors or cytokines have been approved by the U.S. FDA since 2015 as radiomitigators for H-ARS. Two additional agents, amifostine and palifermin, have been approved by the U.S. FDA for very narrow clinical indications (*26*, *87*, *116*); though these agents are used in the clinic for radiation-related limited indications, these are not approved for H-ARS. Of the aforementioned agents, only amifostine is classified as a radioprotector. This agent has poor toxicity and safety profiles, a common limitation with many of the small molecule agents. There are a few additional cytokines and growth factors, such as erythropoietin (EPO), IL-3, and IL-11, that

have been approved by the U.S. FDA for limited indications arising from radiotherapy- and chemotherapy-induced neutropenia in cancer patients. There are several agents that have dual use and are being evaluated as radiation countermeasures for H-ARS and GI-ARS.

The efficacy of radioprotectors/mitigators in the setting of exposure to particulate radiation such as protons or high-linear energy transfer (LET) irradiations such as neutrons and heavy ions is a less explored area since the majority of studies utilized low-LET γ radiation or X rays. Finally, the use of combinations of different agents has not been extensively tested. Thus, combinations of countermeasures with different mechanisms of action may be superior to single agents in the same manner that combination cancer chemotherapy is often superior to treatment with individual agents.

CONCLUSIONS

The above listing of potential agents provides a testament to the research and development effort currently being directed toward the discovery and development of safe and effective medical countermeasures for unintentional radiation exposures. However, the number of useful and fully authorized agents remains remarkably limited. *Radiation Research* has substantially contributed and will continue to contribute to the dissemination of information regarding the development of radiation medical countermeasures through the publication of peer-reviewed research and review articles.

ACKNOWLEDGMENTS

These authors thank HM3 Akeylah K. Woods for her clerical help. The views expressed here do not necessarily represent those of AFRRRI, U.S.UHS, the National Institutes of Health, and the U.S. Department of Defense. This study was supported by NIAID R33-AI080553, JPC-6/7, NIAID 5U19AI067773-18, and AFRRRI AFR-B2-12812.

Received: January 30, 2024; accepted: March 21, 2024; published online: July 5, 2024

REFERENCES

1. Blum M, Eisenbud M. Reduction of thyroid irradiation from ¹³¹I by potassium iodide. *JAMA* 1967; 200(12):1036-40.
2. Noteboom JL, Hummel WA, Broerse JJ, de Vijlder JJ, Vulsma T, Jansen JT, van Bekkum DW. Protection of the maternal and fetal thyroid from radioactive contamination by the administration of stable iodide during pregnancy. An experimental evaluation in chimpanzees. *Radiat Res* 1997; 147(6):691-7.
3. Noteboom JL, Hummel WA, Broerse JJ, de Vijlder JJ, Vulsma T, van Bekkum DW. Protection of the infant thyroid from radioactive contamination by the administration of stable iodide. An experimental evaluation in chimpanzees. *Radiat Res* 1997; 147(6):698-706.
4. Lai EPC, Li C. Actinide Decorporation: A Review on Chelation Chemistry and Nanocarriers for Pulmonary Administration. *Radiat Res* 2022; 198(4):430-43.

5. Osenthal MW, Lindenbaum A. Influence of DTPA therapy on long-term effects of retained monomeric plutonium: comparison with polymeric plutonium. *Radiat Res* 1967; 31(3):506-21.
6. Weiss JF, Landauer MR. History and development of radiation-protective agents. *Int J Radiat Biol* 2009; 85(7):539-73.
7. FDA Approves First New Drug Application for Treatment of Radiation Contamination due to Cesium or Thallium. 03/08/2018. [cited 10/27/2023]. <https://www.fda.gov/drugs/bioterrorism-and-drug-preparedness/fda-approves-first-new-drug-application-treatment-radiation-contamination-due-cesium-or-thallium>
8. Sandal N. Challenges in development and management of orphan drugs—a case study of Prussian blue insoluble. *J Radiol Prot* 2023; 43(4).
9. Shakyawar SK, Mishra NK, Vellichirammal NN, Cary L, Helikar T, Powers R, et al. A review of radiation-induced alterations of multi-omic profiles, radiation injury biomarkers, and countermeasures. *Radiat Res* 2023; 199(1).
10. DiCarlo AL, Bandremer AC, Hollingsworth BA, Kasim S, Laniyonu A, Todd NF, et al. Cutaneous Radiation Injuries: Models, Assessment and Treatments. *Radiat Res* 2020; 194(3):315-44.
11. DiCarlo AL, Cassatt DR, Dowling WE, Esker JL, Hewitt JA, Selivanova O, et al. Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments. *Radiat Res* 2018; 190(6):659-76.
12. DiCarlo AL, Hatchett RJ, Kaminski JM, Ledney GD, Pellmar TC, Okunieff P, Ramakrishnan N. Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. report of an NIAID Workshop, March 26-27, 2007. *Radiat Res* 2008; 169(6):712-21.
13. DiCarlo AL, Horta ZP, Aldrich JT, Jakubowski AA, Skinner WK, Case CM, Jr. Use of Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency. *Radiat Res* 2019; 192(1):99-120.
14. DiCarlo AL, Jackson IL, Shah JR, Czarniecki CW, Maidment BW, Williams JP. Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident. *Radiat Res* 2012; 177(5):717-21.
15. DiCarlo AL, Tamarat R, Rios CI, Benderitter M, Czarniecki CW, Allio TC, et al. Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop. *Radiat Res* 2017; 188(2):e54-e75.
16. Horta ZP, Case CM, Jr., DiCarlo AL. Use of Growth Factors and Cytokines to Treat Injuries Resulting from a Radiation Public Health Emergency. *Radiat Res* 2019; 192(1):92-97.
17. Price PW, DiCarlo AL. Challenges and Benefits of Repurposing Licensed/Approved/Cleared Products for a Radiation Indication. *Radiat Res* 2018; 190(6):654-58.
18. Rios C, Jourdain JR, DiCarlo AL. Cellular Therapies for Treatment of Radiation Injury after a Mass Casualty Incident. *Radiat Res* 2017; 188(2):242-45.
19. Rios CI, DiCarlo AL, Marzella L. Cutaneous Radiation Injuries: Models, Assessment and Treatments. *Radiat Res* 2020; 194(3):310-13.
20. Satyamitra MM, DiCarlo AL, Taliaferro L. Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015. *Radiat Res* 2016; 186(2):99-111.
21. Satyamitra MM, Perez-Horta Z, DiCarlo AL, Cassatt DR, Rios CI, Price PW, et al. NIH Policies and Regulatory Pathways to U.S. FDA licensure: Strategies to Inform Advancement of Radiation Medical Countermeasures and Biodosimetry Devices. *Radiat Res* 2022; 197(5):533-53.
22. Taliaferro LP, DiCarlo AL, Satyamitra MM. NIH Policies and Regulatory Pathways for the Advancement of Radiation Medical Countermeasures and Biodosimetry Tools to U.S. FDA Licensure. *Radiat Res* 2021;
23. Williams JP, Jackson IL, Shah JR, Czarniecki CW, Maidment BW, DiCarlo AL. Animal models and medical countermeasures development for radiation-induced lung damage: report from an NIAID Workshop. *Radiat Res* 2012; 177(5):e0025-39.
24. Winters TA, Cassatt DR, Harrison-Peters JR, Hollingsworth BA, Rios CI, Satyamitra MM, et al. Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency. *Radiat Res* 2023; 199(3):301-18.
25. Hall EJ, Giaccia AJ. Acute radiation syndrome. Radiobiology for the radiologist. Philadelphia, PA: Wolters Kluwer; 2019. p. 214-38.
26. Singh VK, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. *Int J Radiat Biol* 2017; 93(9):851-69.
27. Patt HM, Tyree EB, Straube RL, Smith DE. Cysteine Protection against X Irradiation. *Science* 1949; 110(2852):213-4.
28. Gray LH. Some characteristics of biological damage induced by ionizing radiations. *Radiat Res* 1954; 1(2):189-213.
29. Thomson JF, Carttar MS, Tourtellotte WW. Some observations on the effect of gamma irradiation on the biochemistry of regenerating rat liver. *Radiat Res* 1954; 1(2):165-75.
30. Katz J, Weeks MH, Oakley WD. Relative effectiveness of various agents for preventing the internal deposition of plutonium in the rat. *Radiat Res* 1955; 2(2):166-70.
31. Hilf R, Adachi R, Eckfeldt G. Effect of dietary supplementation with broccoli on x-irradiation-induced enzyme changes in the guinea pig. *Radiat Res* 1961; 15:86-93.
32. Caldwell RW, Heiffer MH. Acute cardiovascular and autonomic effects of WR-2721: a radioprotective compound. *Radiat Res* 1975; 62(1):62-9.
33. Ward WF, Molteni A, Ts'ao CH. Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817. *Radiat Res* 1989; 117(2):342-50.
34. Hanson WR, Grdina DJ. Misoprostol, a PGE1 analog, protects mice from fission-neutron injury. *Radiat Res* 1991; 128(1 Suppl):S12-7.
35. Wu T, Pelus LM, Plett PA, Sampson CH, Chua HL, Fisher A, et al. Further Characterization of Multi-Organ DEARE and Protection by 16,16 Dimethyl Prostaglandin E2 in a Mouse Model of the Hematopoietic Acute Radiation Syndrome. *Radiat Res* 2023; 199(5):468-89.
36. Savla U, Waters CM. Barrier function of airway epithelium: effects of radiation and protection by keratinocyte growth factor. *Radiat Res* 1998; 150(2):195-203.
37. Whittall MH, Inal CE, Jackson WE, 3rd, Miner VL, Villa V, Seed TM. In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. *Radiat Res* 2001; 156(3):283-93.
38. Van der Meeren A, Mouthon MA, Gaugler MH, Vandamme M, Gourmelon P. Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: interactive effect with thrombopoietin. *Radiat Res* 2002; 157(6):642-9.
39. Hao J, Sun L, Huang H, Xiong G, Liu X, Qiu L, et al. Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. *Radiat Res* 2004; 162(2):157-63.
40. Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, et al. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. *Radiat Res* 2009; 171(2):173-9.

41. Berbee M, Fu Q, Boerma M, Wang J, Kumar KS, Hauer-Jensen M. gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. *Radiat Res* 2009; 171(5):596-605.
42. Kulkarni S, Ghosh SP, Satyamitra M, Mog S, Hieber K, Romanyukha L, et al. Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. *Radiat Res* 2010; 173(6):738-47.
43. Brown SL, Kolozsvary A, Liu J, Jenrow KA, Ryu S, Kim JH. Antioxidant diet supplementation starting 24 hours after exposure reduces radiation lethality. *Radiat Res* 2010; 173(4):462-8.
44. Jia D, Koonce NA, Griffin RJ, Jackson C, Corry PM. Prevention and mitigation of acute death of mice after abdominal irradiation by the antioxidant N-acetyl-cysteine (NAC). *Radiat Res* 2010; 173(5):579-89.
45. Vujaskovic Z, Feng QF, Rabbani ZN, Anscher MS, Samulski TV, Brizel DM. Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. *Radiat Res* 2002; 157(6):656-60.
46. Williams JP, Hernady E, Johnston CJ, Reed CM, Fenton B, Okunieff P, Finkelstein JN. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. *Radiat Res* 2004; 161(5):560-7.
47. Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. *Radiat Res* 2005; 163(5):479-87.
48. Guo H, Seixas-Silva JA, Jr., Epperly MW, Gretton JE, Shin DM, Bar-Sagi D, et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. *Radiat Res* 2003; 159(3):361-70.
49. Otsuka K, Koana T, Tomita M, Ogata H, Tauchi H. Rapid myeloid recovery as a possible mechanism of whole-body radioadaptive response. *Radiat Res* 2008; 170(3):307-15.
50. Singh VK, Christensen J, Fatanmi OO, Gille D, Ducey EJ, Wise SY, et al. Myeloid progenitors: a radiation countermeasure that is effective when initiated days after irradiation. *Radiat Res* 2012; 177(6):781-91.
51. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, et al. CBLB613: A TLR 2/6 agonist, natural lipopeptide of *Mycoplasma arginini*, as a novel radiation countermeasure. *Radiat Res* 2012; 177(5):628-42.
52. Singh PK, Wise SY, Ducey EJ, Fatanmi OO, Elliott TB, Singh VK. alpha-Tocopherol succinate protects mice against radiation-induced gastrointestinal injury. *Radiat Res* 2012; 177(2):133-45.
53. Farese AM, Cohen MV, Stead RB, Jackson W, 3rd, Macvittie TJ. Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. *Radiat Res* 2012; 178(5):403-13.
54. Farese AM, Cohen MV, Katz BP, Smith CP, Gibbs A, Cohen DM, MacVittie TJ. Filgrastim improves survival in lethally irradiated nonhuman primates. *Radiat Res* 2013; 179(1):89-100.
55. Romero-Weaver AL, Wan XS, Diffenderfer ES, Lin L, Kennedy AR. Kinetics of neutrophils in mice exposed to radiation and/or granulocyte colony-stimulating factor treatment. *Radiat Res* 2013; 180(2):177-88.
56. Ha CT, Li XH, Fu D, Xiao M, Landauer MR. Genistein nanoparticles protect mouse hematopoietic system and prevent proinflammatory factors after gamma irradiation. *Radiat Res* 2013; 180(3):316-25.
57. Li XH, Ghosh SP, Ha CT, Fu D, Elliott TB, Bolduc DL, et al. Delta-tocotrienol protects mice from radiation-induced gastrointestinal injury. *Radiat Res* 2013; 180(6):649-57.
58. Islam A, Bolduc DL, Zhai M, Kiang JG, Swift JM. Captopril Increases Survival after Whole-Body Ionizing Irradiation but Decreases Survival when Combined with Skin-Burn Trauma in Mice. *Radiat Res* 2015; 184(3):273-9.
59. Roche M, Neti P, Kemp FW, Azzam EI, Ferraris RP, Howell RW. High Levels of Dietary Supplement Vitamins A, C and E are Absorbed in the Small Intestine and Protect Nutrient Transport Against Chronic Gamma Irradiation. *Radiat Res* 2015; 184(5):470-81.
60. Singh VK, Kulkarni S, Fatanmi OO, Wise SY, Newman VL, Romaine PL, et al. Radioprotective Efficacy of Gamma-Tocotrienol in Nonhuman Primates. *Radiat Res* 2016; 185(3):285-98.
61. Cheema AK, Byrum SD, Sharma NK, Altadill T, Kumar VP, Biswas S, et al. Proteomic Changes in Mouse Spleen after Radiation-Induced Injury and its Modulation by Gamma-Tocotrienol. *Radiat Res* 2018; 190(5):449-63.
62. Satyamitra M, Kumar VP, Biswas S, Cary L, Dickson L, Venkataraman S, Ghosh SP. Impact of Abbreviated Filgrastim Schedule on Survival and Hematopoietic Recovery after Irradiation in Four Mouse Strains with Different Radiosensitivity. *Radiat Res* 2017; 187(6):659-71.
63. Horton JA, Li F, Chung EJ, Hudak K, White A, Krausz K, et al. Quercetin inhibits radiation-induced skin fibrosis. *Radiat Res* 2013; 180(2):205-15.
64. Food and Drug Administration H, Office of Product Evaluation and Quality, Center for Devices and Radiological Health [Internet]. October 2022 510(K) clearances - K221218 - Silverlon. [cited 03/01/2024]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf22/K221218.pdf
65. Gao F, Fish BL, Moulder JE, Jacobs ER, Medhora M. Enalapril mitigates radiation-induced pneumonitis and pulmonary fibrosis if started 35 days after whole-thorax irradiation. *Radiat Res* 2013; 180(5):546-52.
66. Medhora M, Gao F, Wu Q, Molthen RC, Jacobs ER, Moulder JE, Fish BL. Model development and use of ACE inhibitors for preclinical mitigation of radiation-induced injury to multiple organs. *Radiat Res* 2014; 182(5):545-55.
67. Zhang K, He X, Zhou Y, Gao L, Qi Z, Chen J, Gao X. Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in Rats. *Radiat Res* 2015; 184(6):611-20.
68. Murigi FN, Mohindra P, Hung C, Salimi S, Goetz W, Pavlovic R, et al. Dose Optimization Study of AEOL 10150 as a Mitigator of Radiation-Induced Lung Injury in CBA/J Mice. *Radiat Res* 2015; 184(4):422-32.
69. Rabender C, Mezzaroma E, Mauro AG, Mullangi R, Abbate A, Anscher M, et al. IPW-5371 Proves Effective as a Radiation Countermeasure by Mitigating Radiation-Induced Late Effects. *Radiat Res* 2016; 186(5):478-88.
70. Wang J, Wang Y, Han J, Mei H, Yu D, Ding Q, et al. Metformin Attenuates Radiation-Induced Pulmonary Fibrosis in a Murine Model. *Radiat Res* 2017; 188(1):105-13.
71. MacVittie TJ, Gibbs A, Farese AM, Barrow K, Bennett A, Taylor-Howell C, et al. AEOL 10150 Mitigates Radiation-Induced Lung Injury in the Nonhuman Primate: Morbidity and Mortality are Administration Schedule-Dependent. *Radiat Res* 2017; 187(3):298-318.
72. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. *Radiat Res* 2014; 181(5):512-20.
73. Gerber SA, Cummings RJ, Judge JL, Barlow ML, Nanduri J, Johnson DE, et al. Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure. *Radiat Res* 2015; 183(1):72-81.
74. Miller RC, Murley JS, Grdina DJ. Metformin exhibits radiation countermeasures efficacy when used alone or in combination

- with sulfhydryl containing drugs. *Radiat Res* 2014; 181(5): 464-70.
75. Toshkov IA, Gleiberman AS, Mett VL, Hutson AD, Singh AK, Gudkov AV, et al. Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation. *Radiat Res* 2017; 187(5):570-80.
 76. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, et al. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. *Radiat Res* 2019; 192(5):473-82.
 77. Bunin DI, Chang PY, Doppalapudi RS, Riccio ES, An D, Jarvis EE, et al. Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen. *Radiat Res* 2013; 179(2):171-82.
 78. Clayton NP, Khan-Malek RC, Dangler CA, Zhang D, Ascah A, Gains M, et al. Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation. *Radiat Res* 2021; 195(2):191-99.
 79. Benderitter M, Herrera-Reyes E, Gigov Y, Souleau B, Huet C, Tromprier F, et al. Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents. *Radiat Res* 2021; 196(6):668-79.
 80. Patterson AM, Sellamuthu R, Plett PA, Sampson CH, Chua HL, Fisher A, et al. Establishing Pediatric Mouse Models of the Hematopoietic Acute Radiation Syndrome and the Delayed Effects of Acute Radiation Exposure. *Radiat Res* 2021; 195(4): 307-23.
 81. Wu T, Orschell CM. The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures. *Int J Radiat Biol* 2023; 99(7):1066-79.
 82. Hamade DF, Espinal A, Yu J, Leibowitz BJ, Fisher R, Hou W, et al. *Lactobacillus reuteri* Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer. *Radiat Res* 2022; 198(1):89-105.
 83. Singh VK, Serebrenik AA, Fatanmi OO, Wise SY, Carpenter AD, Janocha BL, Kaytor MD. The Radioprotectant, BIO 300, Protects the Lungs from Total-Body Irradiation Injury in C57L/J Mice. *Radiat Res* 2023; 199(3):294-300.
 84. Office of the Commissioner U.S.FaDA [Internet]. Radiological and Nuclear Emergency Preparedness Information from FDA (October 2, 2023). 10/2/2023. [cited 01/08/2024]. <https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/radiological-and-nuclear-emergency-preparedness-information-fda>
 85. Singh VK, Seed TM. Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems. *Expert Opin Pharmacother* 2020; 21(3):317-37.
 86. Singh VK, Seed TM. Medical countermeasures for extraterrestrial environments: Current status and future prospects with focus on acute injuries. [cited 10/26/2023]. <https://three.jsc.nasa.gov/articles/Medical%20countermeasures%20for%20space%20environments%20-%20Singh.pdf>
 87. Singh VK, Hanlon BK, Santiago PT, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use. *Int J Radiat Biol* 2017; 93(9):885-906.
 88. Kiang JG, Zhai M, Bolduc DL, Smith JT, Anderson MN, Ho C, et al. Combined Therapy of Pegylated G-CSF and Alxn4100TPO Improves Survival and Mitigates Acute Radiation Syndrome after Whole-Body Ionizing Irradiation Alone and Followed by Wound Trauma. *Radiat Res* 2017; 188(5):476-90.
 89. Wang L, Zhai M, Lin B, Cui W, Hull L, Li X, et al. PEG-G-CSF and L-Citrulline Combination Therapy for Mitigating Skin Wound Combined Radiation Injury in a Mouse Model. *Radiat Res* 2021; 196(1):113-27.
 90. Kiang JG, Smith JT, Anderson MN, Umali MV, Ho C, Zhai M, et al. A novel therapy, using Ghrelin with pegylated G-CSF, inhibits brain hemorrhage from ionizing radiation or combined radiation injury. *Pharm Pharmacol Int J* 2019; 7(3):133-45.
 91. Swift JM, Smith JT, Kiang JG. Ciprofloxacin Therapy Results in Mitigation of ATP Loss after Irradiation Combined with Wound Trauma: Preservation of Pyruvate Dehydrogenase and Inhibition of Pyruvate Dehydrogenase Kinase 1. *Radiat Res* 2015; 183(6): 684-92.
 92. Saunders J, Niswander LM, McGrath KE, Koniski A, Catherman SC, Ture SK, et al. Long-acting PGE2 and Lisinopril Mitigate H-ARS. *Radiat Res* 2021; 196(3):284-96.
 93. Hanson WR. Radiation protection of murine intestine by WR-2721, 16,16-dimethyl prostaglandin E2, and the combination of both agents. *Radiat Res* 1987; 111(2):361-73.
 94. Patchen ML, MacVittie TJ, Jackson WE. Postirradiation glucan administration enhances the radioprotective effects of WR-2721. *Radiat Res* 1989; 117(1):59-69.
 95. Satyamitra MM, Cassatt DR, Taliaferro LP. Meeting Commentary: A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS). *Radiat Res* 2021; 196(4):423-28.
 96. Taliaferro LP, Cassatt DR, Horta ZP, Satyamitra MM. Meeting Report: A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome. *Radiat Res* 2021; 196(4):436-46.
 97. Kiang JG, Blakely WF. Combined radiation injury and its impacts on radiation countermeasures and biodosimetry. *Int J Radiat Biol* 2023; 99(7):1055-65.
 98. Kiang JG, Jiao W, Cary LH, Mog SR, Elliott TB, Pellmar TC, Ledney GD. Wound trauma increases radiation-induced mortality by activation of iNOS pathway and elevation of cytokine concentrations and bacterial infection. *Radiat Res* 2010; 173(3): 319-32.
 99. Zawaski JA, Yates CR, Miller DD, Kaffes CC, Sabek OM, Afshar SF, et al. Radiation combined injury models to study the effects of interventions and wound biomechanics. *Radiat Res* 2014; 182(6):640-52.
 100. Dynlacht JR, Garrett J, Joel R, Lane K, Mendonca MS, Orschell CM. Further Characterization of the Mitigation of Radiation Lethality by Protective Wounding. *Radiat Res* 2017; 187(6): 732-42.
 101. Garrett J, Orschell CM, Mendonca MS, Bigsby RM, Dynlacht JR. Subcutaneous wounding postirradiation reduces radiation lethality in mice. *Radiat Res* 2014; 181(6):578-83.
 102. Loaiza-Bonilla A, Page RD. Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable? *Future Oncol*. 2024; 20(3):145-158.
 103. Kiang JG, Zhai M, Liao PJ, Bolduc DL, Elliott TB, Gorbunov NV. Pegylated G-CSF inhibits blood cell depletion, increases platelets, blocks splenomegaly, and improves survival after whole-body ionizing irradiation but not after irradiation combined with burn. *Oxid Med Cell Longev* 2014; 2014:481392.
 104. Jiao W, Kiang JG, Cary L, Elliott TB, Pellmar TC, Ledney GD. COX-2 inhibitors are contraindicated for treatment of combined injury. *Radiat Res* 2009; 172(6):686-97.
 105. Jourdan MM, Lopez A, Olasz EB, Duncan NE, Demara M, Kittipongdaja W, et al. Laminin 332 deposition is diminished in irradiated skin in an animal model of combined radiation and wound skin injury. *Radiat Res* 2011; 176(5):636-48.
 106. Allen AR, Eilertson K, Sharma S, Baure J, Allen B, Leu D, et al. Delayed administration of alpha-difluoromethylornithine prevents hippocampus-dependent cognitive impairment after single and combined injury in mice. *Radiat Res*. 2014; 182(5):489-98.

107. Gorbunov NV, Kiang JG. Brain Damage and Patterns of Neurovascular Disorder after Ionizing Irradiation. Complications in Radiotherapy and Radiation Combined Injury. *Radiat Res* 2021; 196(1):1-16.
108. Ran XZ, Shi CM, Zheng HE, Su YP, Cheng TM. Experimental research on the management of combined radiation-burn injury in China. *Radiat Res* 2011; 175(3):382-9.
109. Albrecht H, Yang HY, Kiuru M, Maksareekul S, Durbin-Johnson B, Wong MS, et al. The Beta 2 Adrenergic Receptor Antagonist Timolol Improves Healing of Combined Burn and Radiation Wounds. *Radiat Res* 2018; 189(4):441-45.
110. Sproull M, Nishida D, Chang P, Moroni M, Citrin D, Shankavaram U, Camphausen K. Comparison of Proteomic Expression Profiles after Radiation Exposure across Four Different Species. *Radiat Res* 2022; 197(4):315-23.
111. Chopra S, Moroni M, Martello S, Bylicky M, May J, Hritz B, et al. Gene Expression Profiles from Heart, Lung and Liver Samples of Total-Body-Irradiated Minipigs: Implications for Predicting Radiation-Induced Tissue Toxicity. *Radiat Res* 2020; 194(4): 411-30.
112. Burnett LR, Gabard AR, Robinson M, Bourland JD, Dorand JE, Dozier S, et al. Biomolecular Analysis of Beta Dose-Dependent Cutaneous Radiation Injury in a Porcine Model. *Radiat Res* 2019; 192(2):145-58.
113. van den Aardweg GJ, Arnold M, Hopewell JW. A comparison of the radiation response of the epidermis in two strains of pig. *Radiat Res* 1990; 124(3):283-7.
114. Shim S, Jang WS, Lee SJ, Jin S, Kim J, Lee SS, et al. Development of a new minipig model to study radiation-induced gastrointestinal syndrome and its application in clinical research. *Radiat Res* 2014; 181(4):387-95.
115. Hritz B, Legesse B, Ward JM, Kaur A, Holmes-Hampton GP, Moroni M. Investigating the Multi-Faceted Nature of Radiation-Induced Coagulopathies in a Gottingen Minipig Model of Hematopoietic Acute Radiation Syndrome. *Radiat Res* 2021;
116. Singh VK, Garcia M, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. *Int J Radiat Biol* 2017; 93(9):870-84.
117. Bogo V, Jacobs AJ, Weiss JF. Behavioral toxicity and efficacy of WR-2721 as a radioprotectant. *Radiat Res* 1985; 104(2 Pt 1): 182-90.
118. Salem AM, Jackson IL, Gibbs A, Poirier Y, Newman D, Zodda A, et al. Interspecies Comparison and Radiation Effect on Pharmacokinetics of BIO 300, a Nanosuspension of Genistein, after Different Routes of Administration in Mice and Non-Human Primates. *Radiat Res* 2022; 197(5):447-58.
119. Ghosh SP, Pathak R, Kumar P, Biswas S, Bhattacharyya S, Kumar VP, et al. Gamma-Tocotrienol Modulates Radiation-Induced MicroRNA Expression in Mouse Spleen. *Radiat Res* 2016; 185(5):485-95.
120. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, et al. CBLB613: a TLR 2/6 agonist, natural lipopeptide of *Mycoplasma arginini*, as a novel radiation countermeasure. *Radiat Res* 2012; 177(5):628-42.
121. Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. Medical countermeasures against nuclear threats: radionuclide decorporation agents. *Radiat Res* 2008; 170(4):540-8.
122. Gluzman-Poltorak Z, Vainstein V, Basile LA. Association of Hematological Nadirs and Survival in a Nonhuman Primate Model of Hematopoietic Syndrome of Acute Radiation Syndrome. *Radiat Res* 2015; 184(2):226-30.
123. Hu J, Jiao W, Tang Z, Wang C, Li Q, Wei M, et al. Quercetin inclusion complex gels ameliorate radiation-induced brain injury by regulating gut microbiota. *Biomed Pharmacother* 2023; 158: 114142.
124. Zhu X, Li Y, Yue L, Zhou X, Li J, Zhang Y, et al. Quercetin Mitigates Radiation-Induced Intestinal Injury and Promotes Intestinal Regeneration via Nrf2-Mediated Antioxidant Pathway1. *Radiat Res* 2023; 199(3):252-62.
125. Cui W, Hankey KG, Zhang P, Bolduc DL, Bunker R, Xiao M, et al. Identifying Circulating and Lung Tissue Cytokines Associated with Thoracic Irradiation and AEOL 10150 Treatment in a Nonhuman Primate Model. *Radiat Res* 2020; 194(1):81-88.
126. Gao F, Dong W, Liu P, Narayanan J, Fish BL, Jacobs ER, et al. Molecular Changes in miRNA in Irradiated Rat Kidneys: Role of miR-34a and its Vascular Targets in the Notch Pathway. *Radiat Res* 2021; 196(6):611-22.
127. Kim JH, Brown SL, Kolozsvary A, Jenrow KA, Ryu S, Rosenblum ML, et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. *Radiat Res* 2004; 161(2):137-42.
128. Langevin B, Singh P, Plett PA, Sampson CH, Masters A, Gibbs A, et al. Pharmacokinetics and Biodistribution of 16,16 dimethyl Prostaglandin E2 in Non-Irradiated and Irradiated Mice and Non-Irradiated Non-Human Primates. *Radiat Res* 2024; 201(1): 7-18.